Senate Judiciary Hearings Start Next Week The Senate

New Post Public Reply Private Reply Replies (1) Message Board
gimli InvestorJane #55315
661
Senate Judiciary Hearings Start Next Week
The Senate Judiciary Committee will conduct back-to-back hearings next Tuesday and Wednesday entitled “The State of Patent Eligibility in America. The marathon fact-finding hearings come on the heels of the proposed 101 framework released last week. Each of the hearings will include three panels of five speakers.

Judging on the lineups for next week, so far the deck is plainly stacked pro-reform.

The hearings kick off on Tuesday with former Chief Judge of the CAFC Paul Michel, and former USPTO Directors David Kappos and Q. Todd Dickinson, all of which are plainly pro-reform. Two academics are also included on the first Tuesday panel, only one of which can be characterized as anti-reform. I wouldn’t expect a dissenting voice here to in any way outshine the views of the former officials.

The second Tuesday panel includes Robert Armitage (formerly of Eli Lilly) and Mark Lemley (Stanford), both of which are plainly pro-reform as is another academic and private practice attorney on the panel. An attorney from the Electronic Frontier Foundation (EFF) — obviously, anti reform — is also included on this panel, but again, the predominant voices here are pro-reform.

The last Tuesday panel includes a collection of professors and policy fellows that are also predominantly pro-reform.

On Wednesday the bar associations lead off on the first panel. An industry group is included that is anti-reform, but that voice will be offset by the unanimity of all bar associations seeking change.

The second Wednesday panel will include the voice of small inventors (pro-reform) and include Phil Johnson (formerly Johnson & Johnson). While there is a software spokesman that will be anti-reform, the predominant view is once again pro-reform.

Finally, the last Wednesday panel will include multiple voices from Bio/Pharma, obviously pro-reform.

So, on one the pro-reform side of the ledger, you have: former Chief CAFC Judge, two former USPTO Directors, all bar organizations, Bio/Pharma, small inventors, and most academics. On the other, you have a handful of industry organizations (viewed as simply biased in favor of weaker patents) and an academic or two.

Perhaps Tech is looking to storm into the last hearing on June 11th guns blazing, after all positions are laid out. But, even so, the writing is already on the wall here. These hearings are fast-tracked, and the resulting legislation will be introduced very quickly thereafter.

At present, Big Tech is sitting on a very weak hand and momentum is quickly building against it.

Zerify Inc (ZRFY) Stock Research Links

ZRFY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

SmartFinancial Announces Earnings Release and Call Schedule

Updated Category News Views 143

SmartFinancial Announces Upcoming Earnings Release SmartFinancial, Inc. (NYSE: SMBK) has revealed important details regarding its Fourth Quarter earnings for the year 2024. This is an exciting time for investors and stakeholders as the company prepares to share insights into its financial performance. Earnings Release Date and Conference Call Information The earnings...

Continue Reading
IntouchCX Enhances Trust and Safety with WebPurify Acquisition

Updated Category News Views 302

IntouchCX Strengthens Trust and Safety Solutions Through Acquisition IntouchCX has recently made headlines with its acquisition of WebPurify, a leading provider of innovative content moderation solutions that harness the power of artificial intelligence. This strategic move represents a significant advancement in IntouchCX's mission to redefine Trust and Safety solutions,...

Continue Reading
Y-mAbs Therapeutics to Present at Key Investor Conferences

Updated Category News Views 66

Y-mAbs Therapeutics Engages Investors at Upcoming Conferences This September, Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB), a key player in the biopharmaceutical industry, is poised to attract investor interest. The company is known for its innovative radioimmunotherapy and antibody-based treatments designed to transform cancer care. Michael Rossi, the energetic CEO of...

Continue Reading
CorVel Corporation Reports Strong Financial Growth

Updated Category News Views 138

Overview of CorVel's Financial Performance CorVel Corporation (NASDAQ: CRVL) recently unveiled impressive results for the quarter and fiscal year, showcasing strong revenue gains and enhanced earnings metrics. The quarterly revenue hit $232 million, a notable rise from $207 million compared to the same quarter last year. This upward trend is mirrored across the fiscal...

Continue Reading
IQAX Achieves Interoperability Approval for eBL Solutions

Updated Category News Views 178

IQAX eBL Interoperability Approval Highlights IQAX Limited has made significant strides in enhancing its electronic bill of lading (eBL) solution by receiving official approval from the International Group of P&I Clubs (IG P&I Clubs). This approval affirms the capabilities of IQAX eBL's interoperable addendum, empowering users to perform eBL transactions across different...

Continue Reading